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From the Editor’s Desk
MEDICAL STAFF AND 
THE HOSPITAL
A 1907 editorial in JAMA entitled The 
medical staff and the hospital noted: “The 
importance of hospitals to the community is 
now so universally acknowledged that it needs 
no comment; the organization of hospitals, on 
the other hand, and the proper relationship 
which should exist between the medical staff, 
the administrative officers and the public is a 
matter which has been treated in this country 
in far too haphazard a manner.” One hundred 
years later, in Australia in 2007, this 
relationship is even more “haphazard”. 
Medical staff and other health 
professionals have been progressively 
side-lined in the management of hospitals. 
These are now mostly micromanaged 
by top-down structures more attuned 
to political whims than public wishes. 
It should be no surprise that this 
dysfunctional type of management has 
coincided with a time when our public 
hospitals have lurched from crisis to crisis.
The latest crisis involved a major 
metropolitan teaching hospital in New 
South Wales, when disregard of a patient 
having a miscarriage in the chaotic environs 
of a busy emergency department sparked 
media outrage and community dismay and 
disgust. 
Within days, the media exposed other 
instances of perceived poor patient care, 
and the public’s already shaky confidence 
in their hospitals plummeted. In the 
ensuing blame game, it emerged that 
medical staff had been effectively pushed 
aside in the running of their hospitals. 
It seems that hospital management has 
become the business of distant bureaucratic 
silos, populated by people obsessed with 
bottom lines, meetings and memoranda. 
However, hospitals exist for the public, 
and for health professionals who seek to 
serve the community. Health professionals’ 
views about and contributions to the 
management of their hospitals must be 
acknowledged and actively sought. 
Undoubtedly, further bureaucratic failures 
to involve them in management decisions 
will perpetuate the crisis culture in our 
hospitals.
Martin B Van Der Weyden
September MJA BookClub Winners
Congratulations to our two September 
winners: Dr Clare Patterson, Bondi, NSW and 
Dr Viney Joshi, Blackall, QLD. Both have won a 
Triangular Personalised Name Plate from the MJA 
BookClub. To order your own personalised name 
plate, contact Julie Chappell on (02) 9562 6666. Thanks to 
everyone who purchased books from the September MJA BookClub 
and went into the draw. Pictured right is 
Patricia Wall, AMPCo’s Executive Secretary, 
drawing the September winners. To see this 
month’s MJA BookClub’s great offers, 
see page 585 and the inside back cover 
of this issue.
MJABookClub
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Letters
High levels of cannabis use 
persist in Aboriginal 
communities in Arnhem Land, 
Northern Territory
K S Kylie Lee, Alan R Clough and 
Katherine M Conigrave
TO THE EDITOR: Cannabis use is implic-
ated in serious social disruption in many
Northern Territory Aboriginal communities.1
Rising levels of cannabis use were first
reported in Aboriginal communities in Arn-
hem Land in 2002, along with associated
concerns about escalating social impacts and
mental health effects compounded by other
substance use.2
A random sample of 164 people in Arnhem
Land initially interviewed and assessed in
2004 were followed up between October 2005
and June 2006. Their cannabis use was meas-
ured using health worker assessments and self-
reports from interviews. Ethical approval was
granted by the NT Health Department, Men-
zies School of Health Research, and James
Cook University.
Despite a modest decline in cannabis use
in this population between 2002 and 2004,3
the 2005–2006 data indicate persisting high
rates, with 61% of males and 58% of females
(aged 13–34 years) using cannabis at least
weekly.
In a subsample of 60 cannabis users oppor-
tunistically recruited for in-depth interviews in
2005–2006 (37 male and 23 female, aged 13–
42 years), 92% of males and 78% of females
used cannabis daily; 88% reported cannabis
dependence symptoms.
These figures appear to be far higher than
national rates, although national data for sim-
ilar age groups are not available.4,5 Research
has found that, nationally, 6% of males and 3%
of females (aged 14 years) reported using
cannabis in the past week; 18% of males and
13% of females smoked cannabis daily;4 and
21% of adults (aged 18 years) using canna-
bis were dependent.5
Beyond high rates of cannabis use in Arn-
hem Land communities, we also found local
characteristics and perceptions that illustrate
the drug’s distinctive context of use (Box).
Quantities of cannabis used appear to be
higher than in the general population; unem-
ployment among users is higher; and violence
related to diminished supply is common. One
Indigenous community leader described atti-
tudes to cannabis use: “…if there’s a bowl of it
on the table, it is smoked until gone, morning
to night”. Interestingly, some respondents
reported that using cannabis prevents them
from engaging in criminal activity (Box).
While key community members may believe
that cannabis is a tool for social control —
“good for calming down people” — they are
increasingly recognising the significant social
and mental health problems it causes:
People get chained by [cannabis], they
don’t go hunting with family… lots of
fights when they can’t get any … [Canna-
bis] becomes the boss.
Continued concerns about adverse men-
tal health consequences for Aboriginal people
in Arnhem Land who use cannabis seem to be
warranted. Cannabis appears to be firmly
entwined in these isolated communities in a
manner not seen nationally. High levels of
concurrent drug use, particularly tobacco,
raise additional health concerns. Resources are
urgently needed for prevention programs and
targeted interventions for chronic cannabis
users and those with psychiatric comorbidity.
If these patterns of use continue, the implica-
tions for compounding of pre-existing mental
illness and the potential mental health burden
are disturbing.
K S Kylie Lee, PhD Student1 and Research 
Assistant2
Alan R Clough, Associate Professor1,3
Katherine M Conigrave, Staff Specialist in 
Addiction Medicine4,2
1 School of Public Health, Tropical Medicine 
and Rehabilitation Sciences, James Cook 
University, Cairns, QLD.
2 Faculty of Medicine, University of Sydney, 
Sydney, NSW.
3 School of Indigenous Australian Studies, 
James Cook University, Cairns, QLD.
4 Drug Health Services, Royal Prince Alfred 
Hospital, Sydney, NSW.
kyliel@med.usyd.edu.au
1 Wild R, Anderson P. Ampe akelyernemane meke
mekarle: “little children are sacred”. Report of the
Northern Territory Board of Inquiry into the Protec-
tion of Aboriginal Children from Sexual Abuse.
Darwin: NT Government, 2007. http://www.nt.
gov.au/dcm/inquirysaac/pdf/b ipacsa_ final_
report.pdf (accessed Jun 2007).
2 Clough AR, Cairney S, Maruff P, Parker R. Rising
cannabis use in Indigenous communities [letter].
Med J Aust 2002; 177: 395-396. 
3 Clough AR, Lee KSK, Cairney S, et al. Changes in
cannabis use and its consequences over 3 years in a
remote indigenous population in northern Aus-
tralia. Addiction 2006; 101: 696-705.
4 Australian Institute of Health and Welfare. 2004
National Drug Strategy Household Survey: detailed
Characteristics and perceptions of cannabis use in Arnhem Land Aboriginal communities (57 males and 49 females, aged 
13–42 years*) in 2005–2006 compared with available national data from 1997† and 2004‡
* Self-report interview data from an opportunistically recruited sample (using age and sex quotas) of respondents, including people who had never used cannabis as well 
as current and former cannabis users. † People aged  18 years.5 ‡ People aged 14 years.4 § Including ecstasy. ¶ There have been no reliable reports of stimulant, 
benzodiazepine or barbiturate use in these communities. nd = data not available. ◆
National4,5 Arnhem Land* National4,5 Arnhem Land*
Number of cones smoked Per cent unemployed current users / daily users
3.2 (average per day)‡ 7.4 (average per occasion) 25.6%† / nd 60% / Males, 41%; females, 94%
Concurrent drug use Motivations for use
Alcohol (86.2%); stimulants§ (8.2%–27.9%); 
none (10.8%); analgesics (6.6%); 
antidepressants (5.7%); tranquillisers/ 
sleeping pills (4.4%); other (3.9%)‡
Tobacco (100%); alcohol, 
restricted access (40%); 
kava (15%); petrol (5%)¶
nd Socialisation (tempted, lonely, copying friends); 
mood altering (“calms me down”, “gets me going 
in the morning”, “makes my mind straight”); drug 
substitution (from alcohol or petrol); prevents 
criminal activity (stealing or other trouble)
Drug substitution (when cannabis unavailable) Motivations for ceasing/moderating use
Alcohol (60.4%); no substitution (34.2%); 
ecstasy/designer drugs (1.3%); painkillers/ 
analgesics (0.8%); tranquillisers/sleeping pills 
(0.5%); heroin (0.3%); antidepressants (0.2%); 
cocaine/crack (0.1%); other (1.1%)‡
No substitution (83%); 
kava (7%); alcohol (5%); 
petrol (5%)¶
nd Limited supply; starting a family (females); “sick of 
fighting when cannabis runs out”; “made me sick”; 
“mind not straight”; expenses and time spent 
looking for cannabis; employment (males)594 MJA • Volume 187 Number 10 • 19 November 2007
LETTERSfindings. Drug Statistics Series No. 16. Canberra:
AIHW, 2005. (AIHW Cat. No. PHE 66.) http://
www.aihw.gov.au/publications/index.cfm/title/
10190 (accessed Jun 2007).
5 Swift W, Hall W, Teesson M. Cannabis use and
dependence among Australian adults: results from
the National Survey of Mental Health and Wellbe-
ing. Addiction 2001; 96: 737-748. ❏
A national survey of medical 
morning handover report in 
Australian hospitals
Erwin Loh
TO THE EDITOR: I was not surprised by the
results published by Fassett et al1 regarding
clinical handover. Despite being a crucial part
of health care, clinical handover has only
recently become a topical issue in the clinical
governance arena.
In May 2007, the World Health Organiza-
tion launched the “Nine patient safety solu-
tions” to “help reduce the toll of health care-
related harm affecting millions of patients
worldwide”.2 Solution number three relates to
“communication during patient hand-overs”.
Australia is in fact leading the international
collaboration on clinical handover through
the National Clinical Handover Initiative. This
was recently launched by the Australian Com-
mission on Safety and Quality in Health Care
to develop and implement standardised solu-
tions to patient safety problems associated
with clinical handover.3
At a state level, the Victorian Quality Coun-
cil conducted a clinical handover survey of
Victorian health services in May 2006 to
provide an overview of areas of concern relat-
ing to clinical handover.4 The Council
launched a pilot project in 2007 to look at
morning handover processes between junior
doctors. Despite these efforts, hospitals are
still struggling with the issue of clinical
handover at the local level. All health profes-
sionals know that clinical handover is good
clinical practice, but they need to be provided
with the tools to carry it out properly.
Clinical handover, depending on your defi-
nition, includes referral letters from general
practitioners, discharge summaries from hos-
pitals, as well as handover of clinical informa-
tion between different shifts, treating teams,
wards, health professionals and health serv-
ices. It makes sense that the process of
handover of clinical information be carried
out in a standardised format, as the mini-
mum dataset required is consistent for most
circumstances. While there is a need for
standardisation, health organisations must
also be able to devise local innovative solu-
tions that work for them. Information tech-
nology can assist in developing a solution to
this issue.5 For example, different local
health services have already developed in-
house systems for electronic discharge sum-
maries that are integrated with an electronic
health record. While national quality bodies
endeavour to develop national standards and
tools for clinical handover, local health serv-
ices must not sit idly and wait for these, but
must continue to innovate and provide work-
able local solutions for their own health pro-
fessionals. Otherwise, future surveys of
clinical handover will continue to show that a
problem still exists in relation to this issue.
Erwin Loh, Deputy Chief Medical Officer
Clinical Governance Unit, Peter MacCallum 
Cancer Centre, Melbourne, VIC.
erwin.loh@petermac.org
1 Fassett MJ, Hannan TJ, Robertson IK, et al. A national
survey of medical morning handover report in Aus-
tralian hospitals. Med J Aust 2007; 187: 164-165. 
2 World Health Organization. WHO launches “Nine
patient safety solutions”. News release, Washington/
Geneva, 2 May 2007. http://www.who.int/mediacen-
tre/news/releases /2007/pr22/en/index.html
(accessed Sep 2007).
3 Australian Commission on Safety and Quality in




4 Victorian Quality Council. Clinical handover. http://
www.health.vic.gov.au/qualitycouncil/activities/
handover.htm (accessed Sep 2007).
5 Cheah L-P, Amott DH, Pollard J, Watters DAK. Elec-
tronic medical handover: towards safer medical care.
Med J Aust 2005; 183: 369-372. ❏
Matthew J Fassett, Terry J Hannan, 
Iain K Robertson, Steven J Bollipo and 
Robert G Fassett
IN REPLY: Our national survey was specifi-
cally confined to medical morning handover
report, one of many forms of clinical hand-
over.1 The clinical governance area may have
only recently recognised the importance of
clinical handover, but it has been a topical
issue for many years in the clinical arena,
particularly in the United States.2 While
Australia may be leading the way in interna-
tional collaborations, our survey suggests
that this is not translating into clinical prac-
tice. Rather than commissions and councils
providing tools and guidelines to carry out
clinical handover, clinical leaders need to
participate and conduct clinical handover
themselves at the local level. From our previ-
ous experience with morning report, we
provided simple tips on how to implement
clinical handover at the local level,3 andMJA • Volume 187 Number 10 • 19 November 2007 595
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Medical Association guidelines.4
Information technology can be employed
to help with the clinical handover process.
However, when using the all-inclusive defini-
tion of clinical handover suggested by Loh,
this task is complex, as research has shown
that information management needs vary sig-
nificantly between different clinical environ-
ments and would require multiple end-user-
defined outputs from a standardised data
repository.5,6
Clinical handover needs to be implemented
from the bottom up (by clinicians) rather than
from the top down (by commissions).
Matthew J Fassett, Medical Student1
Terry J Hannan, Physician1
Iain K Robertson, Biostatistician2
Steven J Bollipo, Physician1
Robert G Fassett, Professor and Director of 
Medicine1
1 Department of Medicine, Launceston 
General Hospital, University of Tasmania, 
Launceston, TAS.
2 Clifford Craig Medical Research Trust and 
School of Human Life Sciences, University of 
Tasmania, Launceston, TAS.
rob.fassett@dhhs.tas.gov.au
1 Fassett MJ, Hannan TJ, Robertson IK, et al. A
national survey of medical morning handover
report in Australian hospitals. Med J Aust 2007;
187: 164-165. 
2 Harris ED Jr. Morning report. Ann Intern Med 1993;
119: 430-431.
3 Fassett RG, Bollipo SJ. Morning report: an Austra-
lian experience. Med J Aust 2006; 184: 159-161. 
4 Australian Medical Association. AMA clinical
handover guide — safe handover: safe patients.
Canberra: AMA, 2006. http://www.ama.com.au/
web.nsf/doc/WEEN-6XFDSP/$file/Clinical_Hando-
ver.pdf (accessed Oct 2007).
5 McDonald CJ, Overhage JM, Tierney WM, et al.
The Regenstrief Medical Record System: a quarter
century experience. Int J Med Inform 1999; 54:
225-253.
6 Tierney WM, Rotich JK, Hannan TJ, et al. The
AMPATH Medical Record System: creating, imple-
menting, and sustaining an electronic medical
record system to support HIV/AIDS care in western
Kenya. Stud Health Technol Inform 2007; 129: 372-
376. ❏
MIMS is not a stand-alone 
resource
James L Mallows
TO THE EDITOR: I was part of a review of
the Therapeutic Goods Administration
(TGA)-approved product information (PI)
monographs contained in MIMS (Monthly
index of medical specialties) annual with
respect to their poisoning management
advice.1 We looked at the 10 most common
poisonings presenting to Westmead Hos-
pital and another 15 clinically important
poisonings as determined by two of the
authors, and compared the poisoning man-
agement advice given in MIMS to a “gold
standard” derived from a consensus of five
pharmacological resources. For the 25 drugs
examined, 14 monographs contained inac-
curate information, one contained a recom-
mendation for ineffective treatments, and 14
omitted specific treatments or antidotes.
Many of these errors could delay or even
prevent patients receiving currently
accepted and effective therapies for life-
threatening poisonings if MIMS were used as
the primary resource.
The omission of sodium bicarbonate for
ventricular conduction delay and hypoten-
sion in amitriptyline, quinine and thiori-
daz ine  po i son in g s  i s  p ar t i cu l a r l y
problematic. Ventricular conduction delay
and hypotension is often refractory to other
therapies, and delay in bicarbonate adminis-
tration could result in avoidable deaths. The
recommendation of sodium bicarbonate for
ventricular conduction delay and hypoten-
sion was included in the TGA-approved
monograph for amitriptyline in 1984, but
was subsequently removed without qualifi-
cation in 1990 and remains absent. Cypro-
heptadine, an important therapy for
serotonin syndrome, is not included in the
TGA-approved monograph for sertraline,
and its delay could result in avoidable mor-
bidity. Atropine for verapamil-induced
bradycardia is a simple and intuitive ther-
apy; however, its omission from the TGA-
approved monograph could again result in
avoidable morbidity and mortality.
We also found potentially dangerous
treatments recommended in the TGA-
approved monographs not covered by the
consensus opinion. These included intra-
venous amphetamine or intramuscular
ephedrine to counter the sedative effects of
promethazine poisoning, administration of
enteric-coated ammonium chloride tablets
to increase urinary excretion in chloroquine
poisoning, and forced osmotic diuresis
using a urea or mannitol infusion for lithium
poisoning. These treatments are out of the
Dark Ages, and their use should be consid-
ered negligent.
Based on this and other reports in previous
editions of the Journal, the TGA-approved PI
monographs contain inaccurate, inadequate,
out-of-date or potentially dangerous informa-
tion relating to poisoning management
advice, paediatric drug dosages,2 drug inter-
actions,3 breastfeeding mothers,4 and various
thyroid medications.5 How can we use MIMS
for anything other than simple drug formula-
tion information? Surely, to anyone who
wishes to practise up-to-date, safe, evidence-
based medicine, the answer must be that we
cannot.
It is time for the TGA to take up its role as
regulator and insist on updated and accurate
PI monographs from the pharmaceutical
companies.
James L Mallows, Staff Specialist
Emergency Department, Nepean Hospital, 
Sydney, NSW.
mallowj@wahs.nsw.gov.au
1 Mallows J, Chan B, Graudins A. Quality of poisoning
management advice in the Monthly Index of Medical
Specialties Annual. Emerg Med Australas 2005; 17:
511-519.
2 Tan E, Cranswick NE, Rayner CR, Chapman CB.
Dosing information for paediatric patients: are they
really “therapeutic orphans”? Med J Aust 2003; 179:
195-198. 
3 Sweidan M, Reeve JF. Deficiencies in drug interac-
tion information [letter]. Med J Aust 2007; 186: 483. 
4 Amir LH. Medicines and breastfeeding: information
is available on safe use [letter]. Med J Aust 2007; 186:
485. 
5 Stockigt JR. Barriers in the quest for quality drug
information: salutary lessons from TGA-approved
sources for thyroid-related medications. Med J Aust
2007; 186: 76-79. ❏
David T Graham
IN REPLY: An article by Stockigt1 and fol-
low-up correspondence from Mallows raised
concerns about the limitations of approved
product information (PI).
The purpose of PI needs to be realised. The
document is not intended to act as a textbook
of medicine or general management of
patients, but is intended to contain sufficient
information to allow a health professional, in
average circumstances, to use the specified
medicine safely and to refer to other sources
of information and expertise should they be
required. The PI covers uses of the medicine
evaluated and approved by the Therapeutic
Goods Administration (TGA).
The sponsor of the medicine is responsible
for maintaining the PI, and the TGA has
procedures in place to support their timely
updating. On occasions, the TGA initiates
reviews of PI when a need is identified.
Health professionals, especially specialists,
are important in identifying possible
improvements in PI, based on their experi-
ence, knowledge or awareness of current
medical practice. The TGA encourages physi-
cians who have suggestions to approach the
sponsor of the medicine or the TGA.
It is not possible to address in detail the
article by Stockigt1 or the letter by Mal-596 MJA • Volume 187 Number 10 • 19 November 2007
LETTERSlows. The thyroid PI documents have been
reviewed by the sponsor companies, and
changes have been made where evidence
supports this.
However, as indicated above, there are
limitations on the role of PI. Mallows raises
the issue of complex management instruc-
tions on overdosage, including the specifics
of bicarbonate administration for potential
metabolic acidosis. The PI documents for
the named products do mention that over-
dose patients are likely to develop such
complications, and that they require
admission to hospital and management by
appropriate specialists; intensive care
admission is recommended in several of
the documents. It is arguable how much
further detail is required. The PI cannot
replace careful consideration of the indi-
vidual circumstances of the patient com-
bined with expert knowledge of patient
management.
PIs are complex documents. The TGA is
currently considering the format of the PI
and whether it can be rearranged to better
balance provision of basic messages and
more complex material in separate presen-
tations.
David T Graham, National Manager
Therapeutic Goods Administration, Canberra, 
ACT.
david.graham@health.gov.au
1 Stockigt JR. Barriers in the quest for quality drug
information: salutary lessons from TGA-approved
sources for thyroid-related medications. Med J Aust
2007; 186: 76-79. ❏
International conferences on 
rare diseases: initiatives in 
commitment, patient care 
and connections
Yvonne A Zurynski, Katie N Reeve and 
Elizabeth J Elliott
TO THE EDITOR: The recent conference
report by Knight and Taruscio highlights
the need for a coordinated effort to fill
knowledge gaps and improve service provi-
sion for Australians with rare diseases.1
Although, by definition, individual rare
diseases occur infrequently, there are about
6000 rare diseases affecting 6%–10% of the
population.2,3 This equates to 1.2 million
Australians, 30 million people in Europe
and 25 million in the United States. By
comparison, diabetes affects 1.4 million
Australians.4
It is increasingly acknowledged that low
prevalence does not equate to low impact.
Rare diseases often have their onset in
childhood, continue throughout life, are
difficult to diagnose, are disabling, and
have significant impact on patients, their
families, the community and health serv-
ices.2,5 However, rare diseases receive such
scant attention that they have been dubbed
“orphan” diseases. Lack of epidemiological
and scientific data has hindered develop-
ment of evidence-based practice, policy
and services.
To tackle the problem of rare diseases,
the European Union, the US, Canada and
New Zealand have established policies and
agencies to foster research, and develop
resources for clinicians, community infor-
mation services, and appropriate health
facilities. The National Institutes of Health
in the US established the Office of Rare
Diseases because:
. . . rare disease research requires the
collaboration of scientists from mul-
tiple disciplines and the capacity to
share access to geographically distrib-
uted national research resources and
patient populations . . . knowledge
about rare diseases may offer leads for
scientific advancement in other rare
diseases and in more common dis-
eases.6
There is no coordinated national effort or
policy in Australia.
Currently, there are 14 national paediat-
ric surveillance units, including the Aus-
tralian Paediatric Surveillance Unit (APSU),
to which paediatricians contribute epi-
demiological, clinical and outcome data on
rare conditions of childhood.7 These data
inform development of health policy and
improved diagnosis and clinical manage-
ment, and result in the establishment of
cohorts, thereby enabling further research.7
The APSU is developing information
resources for clinicians and the community
on rare infections, genetic disorders, men-
tal health conditions and injuries in chil-
dren. In Australia, the APSU is the only
provider of prospective national data on up
to 16 rare childhood diseases concurrently,
but it receives no ongoing core funding.
Sound evidence is needed to underpin
development of policy and services. Sound
evidence requires sound research into the
causes, management and effects of rare
diseases. Australian clinicians, researchers
and, most importantly, patients and their
families deserve the benefits of a coordi-
nated national plan to address the common
burden of rare diseases.
Yvonne A Zurynski, Assistant Director1
Katie N Reeve, Research Officer1
Elizabeth J Elliott, Director1 and NHMRC 
Practitioner Fellow and Professor2
1 Australian Paediatric Surveillance Unit, The 
Children’s Hospital at Westmead, Sydney, 
NSW.
2 Discipline of Paediatrics and Child Health, 
University of Sydney, Sydney, NSW.
apsu@chw.edu.au
1 Knight AW, Taruscio D. International conferences
on rare diseases: initiatives in commitment, patient
care and connections. Med J Aust 2007; 187: 74-76. 
2 US Department of Health and Human Services.
National Institutes of Health Office of Rare Diseases
[website]. http ://rarediseases.info.nih.gov/
(accessed Aug 2007).
3 European Organisation for Rare Diseases. Rare dis-
eases: understanding this public health priority. Nov
2005. http://www.eurordis.org/IMG/pdf/princeps_
document-EN.pdf (accessed Aug 2007).
4 Dunstan DW, Zimmet PZ, Welborn TA, et al. The
rising prevalence of diabetes and impaired glucose
tolerance: the Australian Diabetes, Obesity and
Lifestyle Study. Diabetes Care 2002; 25: 829-834.
5 Dunkelberg S. A patient’s journey: our special girl.
BMJ 2006; 333: 430-431.
6 US Department of Health and Human Services.
National Institutes of Health. NIH news. National
Centre for Research Resources. NIH establishes rare
diseases clinical research network. http://
www.nih.gov/news/pr/nov200 3/ncr r-03.htm
(accessed Oct 2007).
7 Grenier D, Elliott EJ, Zurynski Y, et al. Beyond
counting cases: public health impacts of national




Roger W Byard and Neil Matthews
TO THE EDITOR: In recent years, there has
been an increase in the use of highly mobile
three-wheel strollers that facilitate parental
activities such as jogging. Unfortunately, the
very design feature that enables fast transit
over uneven ground also makes it possible for
unsupervised strollers to move rapidly into
situations that may be highly dangerous.
Within the past year in South Australia
there have been two separate incidents where
infants, one aged 5 months and the other
aged 10 months, died after being immersed
in the Torrens River. They had both been
strapped into three-wheel strollers. In both
instances, carers, who had been walking or
jogging in the park along the banks of the
river, were momentarily distracted — one by
a mobile phone call and the other while
attempting to use a plastic bag dispenser. The
strollers had not had their front wheelsMJA • Volume 187 Number 10 • 19 November 2007 597
LETTERSlocked or their brakes engaged, or been
attached to the carers by wrist straps and so
were unrestrained, enabling them to roll rap-
idly forwards into the water. Police re-enact-
ments confirmed the scenarios described by
the carers.
While three-wheel strollers have safety fea-
tures, such as brakes and sometimes wrist
straps, these are not always used. Although
consumer organisations have listed a series of
recommendations for users of these strollers,
this advice is not always being followed. The
recommendations include never leaving a
child unattended in one of these strollers,
always using a wrist safety strap, always
engaging the brake when stationary, and
locking the front wheel when jogging to
prevent swivelling. In addition, specific
warnings are issued about stopping on
slopes, being distracted by mobile phone
calls, and being particularly careful near
water, roads and railway lines.1
Drowning of infants and toddlers in rivers
is an uncommon event, with only two cases
documented of a total 32 drowning deaths of
children under the age of 2 years in South
Australia over the 35 years from 1963 to
1998 (rate, 6.25%).2 Thus, the occurrence of
two drowning deaths within 4 months associ-
ated with three-wheel stroller use in parks
next to a river is of concern.
While mandatory requirements for safety
devices such as parking brakes and tether
straps will take effect on 1 July 2008,3 this
legislation will have little effect if the devices
are not used. Parents and carers must be
made aware that infants or toddlers in three-
wheel strollers near water are at risk of
immersion and drowning. Such warnings
should be clearly specified on these products.
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Herpes compunctorum: 
cutaneous herpes simplex virus 
infection complicating 
tattooing
Catherine S Marshall, Felicity Murphy, 
Shannon E McCarthy and 
Allen C Cheng
TO THE EDITOR: A 30-year-old man
presented with pain, swelling and dis-
charge from lesions on his left arm. He had
undergone extensive tattooing on the arm
3 days earlier at a commercial tattoo opera-
tion, where single-use needles were used,
with initial drawing of lines followed by
additional shading. The patient com-
plained of severe neuropathic pain in the
arm, which was greater than would be
expected from uncomplicated bacterial cel-
lulitis. He did not give a history of oral or
genital herpes and had previously been
tattooed without complication. On presen-
tation, the patient had a low-grade fever
(37.9°C), a heart rate of 80 beats/min and
blood pressure of 130/80 mmHg. He had
no neurological deficit.
Vesicular lesions were visible in the
region of the tattoo marks, predominantly
affecting areas of shading and with minimal
spread outside tattooed areas (Box). A bac-
terial swab of the lesions grew methicillin-
sensitive Staphylococcus aureus, and a
polymerase chain reaction test of vesicular
fluid was positive for herpes simplex virus
type 1 (HSV-1). The patient was com-
menced on intravenous flucloxacillin (1 g
four times daily) and oral famciclovir
(250 mg three times daily). He required
ongoing inpatient management for pain
relief. Five days after development of the
lesions, HSV-1 serology demonstrated posi-
tive results for IgM and IgG. An HIV test
was negative. The patient’s lesions slowly
resolved, and he was discharged 7 days
after admission.
Most concerns regarding infectious com-
plications of tattooing have focused on
transmission of blood-borne viruses, but
superficial infections with other pathogens
have also been described.1 The personal
care and body art industries are regulated
in Australia to minimise the transmission of
blood-borne infection,2 and most state and
territory authorities also publish infection
control guidelines.
Herpes dermatitis is often confused with
bacterial infection, although co-infection
may occur. This distinction is clinically
important, as antibiotics and surgical deb-
ridement are not usually required for her-
petic infections, and herpetic lesions may
recur. Secondary herpetic infection com-
plicating skin disease is most commonly
associated with eczema (eczema herpeti-
cum) or other skin diseases (Kaposi’s vari-
celliform eruption), and minor skin
trauma, such as in herpetic whitlow or
herpes gladiatorum.3,4 We are not aware of
any previous reports of herpetic infection
complicating tattoo placement.
The distribution of herpetic lesions in
our patient suggested that the needle used
for tattoo shading became contaminated
with HSV-1 during the course of tattoo
placement, but it is also possible that
superinfection occurred through damaged
skin after the procedure. We propose the
term “herpes compunctorum” to describe
this condition.
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LETTERSDriving assessment and 
rehabilitation after stroke
Zoe A Allen, Julie Halbert and 
Lydia Huang
TO THE EDITOR: Helping patients who
have had a stroke return to driving when
possible should be an important focus in
rehabilitation wards. The National Stroke
Foundation supports a three-stage approach
to assessing ability to drive, comprising phys-
ical and cognitive assessment, an off-road
driving test and an on-road driving test.1
Austroads is the association of Australian and
New Zealand road transport and traffic
authorities, which aims to improve road and
road transport outcomes. It provides clear
guidelines on criteria for licence and assess-
ment after stroke, but the implementation of
these guidelines varies in practice.2
We conducted a review of 53 consecutive
patients with a primary diagnosis of stroke
admitted to a specialised rehabilitation ward
over a 6-month period between January and
July 2007. The mean age of the sample
population was 77.0 years (SD, 10.7 years),
and cognition score (Functional Independ-
ence Measure) on discharge was 28.3 (SD,
7.1) (maximum possible score, 35). Each
patient completed a survey on driving his-
tory. Case notes were reviewed for medical
factors associated with admission, any nota-
tions about driving, and actions taken
regarding driving. Patients were telephoned
6 months after the date of the stroke to
determine whether they had resumed driv-
ing and, if not, to explore the reasons.
At the time of admission, 26 of the 53
patients held a current drivers licence, a
proportion higher than the South Australian
state rate of less than 10% for people aged
75 years and over. At the time of discharge,
12 of the 26 patients had their licences
cancelled, 11 were referred for medical
review after discharge without formal sus-
pension, two were referred for occupational
therapy driving assessment, and one was
advised not to drive for 6 weeks. At 6
months, only five of the 26 patients (19%)
had resumed driving, with one having
regained a cancelled licence; six patients
cited “lack of confidence” as the reason for
not resuming driving.
Reasons for the doctors’ decisions regard-
ing driving were poorly documented in the
case notes, and the time frame proposed for
medical review ranged from 1 to 4 months.
Austroads requires a minimum time of 4
weeks post-stroke before patients can
resume driving, but does not specify a time
frame for medical or on-road reassessment.
Commonly, patients undergoing acute
rehabilitation are still within the 4-week
period, and assessments regarding return to
driving are premature. The low rate of refer-
ral to available occupational therapy on-
road driving assessment may reflect poor
awareness of available hospital resources
and online guidelines.
While overseas studies of post-stroke
populations indicate a return-to-driving rate
between 30% and 58%,3-5 our rate was
19%. This low rate may represent a lack of
formal assessment and driver rehabilitation
opportunities. The benefits of formal driving
assessment and training are supported by
recent studies which found that licensed
drivers post-stroke did not have an
increased incidence of either car accidents
or driving violations.6
While most doctors in the rehabilitation
ward seemed to have understood the need
to address the issue of driving, more formal
training in this field is required for doctors.
Zoe A Allen, Registrar1
Julie Halbert, Senior Research Fellow1
Lydia Huang, Consultant in Rehabilitation 
Medicine2
1 Department of Rehabilitation and Aged Care, 
Flinders University, Adelaide, SA.
2 Division of Rehabilitation, Aged Care and 
Allied Health, Repatriation General Hospital, 
Adelaide, SA.
zoe.allen@rgh.sa.gov.au
1 National Stroke Foundation. Clinical guidelines for




2 Austroads. Assessing fitness to drive. http://
www.austroads.com.au/aftd/index.html (accessed
Sep 2007).
3 Fisk G, Owsley C, Pulley L. Driving after stroke:
driving exposure, advice, and evaluations. Arch
Phys Med Rehabil 1997; 78: 1338-1345.
4 Lee N, Tracy J, Bohannon R, Ahlquist M. Driving
resumption and its predictors after stroke. Conn
Med 2003; 67: 387-391.
5 Legh-Smith J, Wade D, Hewer R. Driving after a
stroke. J R Soc Med 1986; 79: 200-203.
6 Akinwuntan A, Feys H, DeWeerdt W, et al. Determi-
nants of driving after stroke. Arch Phys Med Rehabil
2002; 83: 334-341. ❏
Distribution of body mass index 
values for men and women in 
three different age groups*
* 24–27 years, 757 men and 854 women; 28–30 
years, 767 men and 807 women; and 31–34 
years, 673 men and 691 women in the 20-year 
follow-up of the 1985 Australian School Health 
and Fitness Survey. ◆
Correction
Re: “Overweight and obesity from 
childhood to adulthood: a follow-up of 
participants in the 1985 Australian Schools 
Health and Fitness Survey”, the letter by 
Alison J Venn, Russell J Thomson, Michael D 
Schmidt, Verity J Cleland, Beverley A Curry, 
Hanni C Gennat and Terence Dwyer, in the 3 
September issue of the Journal (Med J Aust 
2007; 187: 314-315).
The Box showing the distribution of body
mass index values for men and women in
three different age groups showed two
identical graphs of the data for men. The
graphs were clearly different in the ori-
ginal submission, but the data supplied
were incorrect. The correct graphs are
shown here.MJA • Volume 187 Number 10 • 19 November 2007 599
